news
SARS-CoV-2 also uses neuropilin-1 to infect human cells
Researchers reveal that SARS-CoV-2 is more infectious than SARS-CoV because it can use both ACE2 and neuropilin-1 to infect cells.
List view / Grid view
Severe Acute Respiratory Syndrome (SARS)
news
Drug target to combat three coronavirus diseases identified by researchers
Researchers studying the PLpro binding site of three coronaviruses, including SARS-CoV-2, say the BL2 loop could be targeted by antiviral drugs.
news
Researchers suggest IgA antibodies are better at neutralising SARS-CoV-2
Scientists have developed a novel secretory immunoglobulin A (sIgA) serotype antibody that binds more effectively to the spike protein of SARS-CoV-2 than some IgG antibodies.
news
Near-identical protein on SARS and COVID-19 could be targeted by FDA-approved drugs
According to researchers, drugs that target envelope protein E on the SARS viral membrane could also be used to target a similar protein on COVID-19.
news
LY6E identified as potential immunoprotein against SARS-CoV-2
A study has demonstrated that the LY6E protein inhibits SARS-CoV-2 infection in human cell cultures, so a drug mimicking it could be a therapy for COVID-19.
news
“Potent” antibodies provide protection from COVID-19 in cell cultures, finds study
Newly discovered antibodies found in the blood of recovered COVID-19 patients could provide robust protection against SARS-CoV-2, say researchers.
news
Naphthalene-based PLpro inhibitors show potential as COVID-19 therapeutics
A group of small molecules called naphthalene-based PLpro inhibitors have been shown to block the activity of a SARS-CoV-2 protein, demonstrating potential as COVID-19 therapeutics.
news
Protease inhibitors could be highly effective against SARS-CoV-2
Researchers reveal the main protease (Mpro) of SARS-CoV-2 is highly sensitive to disruption, therefore Mpro inhibitors could be a potential COVID-19 therapeutic.
article
Antibodies against viral disease: highlighting technologies behind COVID-19 antibody therapy
Amid the rush to develop an effective vaccine against COVID-19, antibody therapy has become a major strategy to ameliorate and treat cases of severe disease. Armed with the capacity to neutralise pathogens and orchestrate the immune system, promising antibody candidates for multiple viral indications, including HIV, continue to emerge. Technology…
article
Using scientific literature to aid the development of a safe and effective COVID-19 vaccine
Researchers in the US describe how they utilised previously published scientific literature to guide the design of their potential COVID-19 vaccine.
news
Human enzymes could be driving COVID-19 evolution, suggest researchers
Post-infection genome editing could be the cause of mutations in the SARS-CoV-2 virus responsible for the COVID-19 pandemic, driving its evolution.
news
Antibody named S309 from SARS patient shows promise against COVID-19
An antibody called S309, identified in a blood sample from a SARS patient, inhibits related coronaviruses, including SARS-CoV-2, researchers have found.
news
Study finds coronaviruses do not readily induce cross-protective antibody responses
Researchers have found that antibodies produced in response to SARS and COVID-19 are cross-reactive, but not cross protective in cells and mice.
news
Scientists stress need for research into COVID-19 symptom treatment
In a new article, researchers highlight the need for treatments to combat the potentially lethal overreaction of the immune system in the progression of COVID-19.
news
Molecules derived from ticks could be used as late-stage COVID-19 treatment
Researchers have found that molecules from ticks called Evasins have the potential to halt cytokine storms, the leading cause of COVID-19 fatalities.